DR.REDDY'S LABORATORIES LTD. - ZEMBRACE" SymTouch" (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.

19 Apr 2016

Dr Reddys Laboratories Ltd has informed BSE regarding a Press Release dated April 19, 2016 titled "ZEMBRACE" SymTouch" (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.".

Source: BSE India

View all announcements for DR.REDDY'S LABORATORIES LTD.

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist

DR.REDDY'S LABORATORIES LTD. - ZEMBRACE&quot; SymTouch&quot; (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.

DR.REDDY'S LABORATORIES LTD. - ZEMBRACE" SymTouch" (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.